Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes

Trial Profile

Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2012

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Diabetic nephropathies; Renal impairment
  • Focus Pharmacodynamics
  • Most Recent Events

    • 23 Oct 2012 Planned end date changed from 1 Dec 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov.
    • 23 Oct 2012 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 07 May 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top